GILEAD SCIENCES, INC. — SEC Form 4 filings
SEC reporting owner CIK 882095. 12 Form 4 filings on record with FilingPulse; latest filed 2026-05-27.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-01-31 to 2026-05-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 8 legs across 8 filings — 23,172,878 shares, $377,317,622 total (shares × price as filed on priced legs).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: purchase of 15,238,095 shares @ $21.00 ($319,999,995) in Arcus Biosciences, Inc., filed 2024-01-31.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | 10% owner | 2 | 2 legs · 16,601,731 sh · $334,999,991 | — | — |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | 10% owner | 4 | 3 legs · 3,415,919 sh · $20,098,464 | — | 4 |
| Kyverna Therapeutics, Inc. (KYTX) | 10% owner | 1 | 1 leg · 910,000 sh · $20,020,000 | — | 3 |
| Xilio Therapeutics, Inc. (XLO) | 10% owner | 5 | 2 legs · 2,245,228 sh · $2,199,167 | — | 9 |
Form 4 filings — GILEAD SCIENCES, INC.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-27 | 4 | ASSEMBLY BIOSCIENCES, INC. (ASMB) | Grant/award (A): 471,698 @ $26.50 | EDGAR |
| 2026-02-17 | 4 | Xilio Therapeutics, Inc. (XLO) | Purchase (P): 3,739,000 (derivative) @ $0.53 | EDGAR |
| 2025-12-01 | 4 | Xilio Therapeutics, Inc. (XLO) | Option exercise/expiry (X): 13,335,000 (derivative) @ $0.75 · Option exercise/expiry (X): 13,335,000 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | ASSEMBLY BIOSCIENCES, INC. (ASMB) | Purchase (P): 2,295,920 · Purchase (P): 1,147,960 (derivative) · Purchase (P): 1,147,960 (derivative) | EDGAR |
| 2025-06-06 | 4 | Xilio Therapeutics, Inc. (XLO) | Purchase (P): 13,335,000 (derivative) · Purchase (P): 13,335,000 (derivative) · Purchase (P): 13,335,000 (derivative) · Purchase (P): 13,335,000 (derivative) | EDGAR |
| 2025-02-20 | 4 | Arcus Biosciences, Inc. (RCUS) | Purchase (P): 1,363,636 @ $11 | EDGAR |
| 2024-12-23 | 4 | ASSEMBLY BIOSCIENCES, INC. (ASMB) | Purchase (P): 940,499 @ $21.37 | EDGAR |
| 2024-12-19 | 4 | Xilio Therapeutics, Inc. (XLO) | Purchase (P): 1,759,978 @ $1.04 · Purchase (P): 6,092,816 (derivative) @ $1.04 | EDGAR |
| 2024-06-20 | 4 | ASSEMBLY BIOSCIENCES, INC. (ASMB) | Purchase (P): 179,500 · Purchase (P): 179,500 (derivative) | EDGAR |
| 2024-04-03 | 4 | Xilio Therapeutics, Inc. (XLO) | Purchase (P): 485,250 @ $0.76 · Purchase (P): 3,882,450 (derivative) @ $0.76 | EDGAR |
| 2024-02-13 | 4 | Kyverna Therapeutics, Inc. (KYTX) | Conversion (C): 3,216,119 · Purchase (P): 910,000 @ $22 · Conversion (C): 6,890,744 (derivative) @ $0 · Conversion (C): 7,746,139 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Arcus Biosciences, Inc. (RCUS) | Purchase (P): 15,238,095 @ $21 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=882095 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →